Thyrogen

DRUG3 trials

Sponsors

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Genzyme, a Sanofi Company

Conditions

HypothyroidismThyroid CancerThyroid Neoplasms

Phase 2

The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer

RecruitingNCT03841617

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Thyroid Cancer

Start: 2019-07-29End: 2035-11-01Target: 30Updated: 2026-09-09

Phase 4

Study of Radioiodine (131-I) Uptake Following Administration of Thyrogen and Hypothyroid States During Thyroid Hormone Withdrawal.

CompletedNCT00001730

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Hypothyroidism, Thyroid Neoplasms

Start: 1997-12-31End: 2000-04-30Target: 20Updated: 2008-03-04

Unknown Phase

A Retrospective Observational Study Comparing Two Different Treatment Options in Thyroid Cancer Patients With T4 Tumours

CompletedNCT01736163

Genzyme, a Sanofi CompanyThyroid Cancer

Start: 2012-05-31End: 2012-08-31Updated: 2015-03-23